Longhorn Vaccines and Diagnostics to Present at 2021 BIO Digital

Bethesda, MD, June 10, 2021 – Longhorn Vaccines & Diagnostics, an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, announced today that it has been selected to deliver a presentation on the past success and future opportunities for its lead product, PrimeStore MTM (Molecule Transport Medium) as well as introduce the rest of the company’s product line, at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 and 14-18, 2021, and presentations will be available on-demand throughout the event.

Jeff Fischer, President and Co-Founder, will present the company and PrimeStore MTM, which was the first microbial nucleic acid storage and transport device cleared by the U.S. Food and Drug Administration. PrimeStore MTM quickly inactivates viruses (including COVID-19, influenza), bacteria (including tuberculosis), and pathogens within the sample while preserving RNA and DNA for testing. The presentation will be available to registered attendees beginning at 9 a.m. ET on June 10.

“While PrimeStore MTM and the Longhorn product line is well known within the Molecular Diagnostic community, we’re looking forward to presenting PrimeStore MTM to a wider pharmaceutical and biotech audience at BIO so that attendees can see the impact that our state-of-the-art diagnostic tools have on improving the safety, sensitivity, and cost efficiency of clinical trials, point of care, and hospital testing,” said Jeff Fischer, President at Longhorn. “In the past year-and-a-half we’ve been able to demonstrate our company’s ability to deliver high volume and custom solutions directly and through our current partnerships.”

Attendees at BIO Digital will be able to view Longhorn’s Company Presentation before live meetings in the BIO One-on-One Partnering™ system begin on June 14.  To meet with Longhorn at BIO Digital, information is available here.

 

About PrimeStore MTM

PrimeStore MTM (Molecule Transport Medium) was the first microbial nucleic acid storage and transport device cleared by the U.S. Food and Drug Administration (U.S. FDA). It is indicated to rapidly inactivate viruses (including Influenza), bacteria (including Mycobacterium tuberculosis) and high consequence veterinary pathogens (including ASFv, CSFv, FMDv, HPAI, NDv) within the sample and stabilize the RNA and DNA to provide safer and more efficient workflow for molecular testing and sequencing. 

PrimeStore MTM alleviates the challenge of collecting a quality sample and transporting it in a safe and timely manner to any laboratory that can effectively test that sample using modern molecular platforms. Researchers worldwide have used the device successfully, including in remote regions of Nepal, India, China, South Africa, Peru, Pakistan, Papua New Guinea, and Ukraine, as well as densely populated cities such as Mumbai, Pretoria, Macau and Singapore.

PrimeStore MTM has multiple issued patents in the United States and worldwide.

 

About BIO

BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Subscribe to Good Day BIO.
 

Contact:

Longhorn Vaccines & Diagnostics
Jeffrey Fischer
Email: jeff@lhnvd.com 

 

Media:
Alexis Feinberg – Westwicke/ICR PR
Email: alexis.feinberg@westwicke.com 

Mark Corbae – Westwicke/ICR PR
Email: Mark.Corbae@westwicke.com

Previous
Previous

In the clinic for July 7, 2021

Next
Next

Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017-18 (PHIRST): a population cohort study - The Lancet Global Health